<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01106118</url>
  </required_header>
  <id_info>
    <org_study_id>14872</org_study_id>
    <secondary_id>LV0901</secondary_id>
    <nct_id>NCT01106118</nct_id>
  </id_info>
  <brief_title>Therapeutic Effectiveness of Vardenafil in Patients With Erectile Dysfunction and Metabolic Syndrome in Daily Clinical Practice</brief_title>
  <acronym>REVITALISE</acronym>
  <official_title>Therapeutic Effectiveness of Vardenafil in ED Patients With the Metabolic Syndrome in Daily Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this international non-interventional study is to investigate the
      therapeutic effectiveness of vardenafil (film-coated tablet) in Erectile Dysfunction patients
      with the Metabolic Syndrome in daily clinical practice. It will include a large number of
      patients with various underlying conditions with different cultural and demographic
      backgrounds from different geographic areas.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of patients with a clinically relevant, intra-individual improvement in erectile function defined as an increase of 4 points in the erectile function domain of the International Index of Erectile Function (IIEF)</measure>
    <time_frame>After approx 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients with an increase of 5 points in the Erectile Dysfunction domain of the IIEF after approx. 12 weeks</measure>
    <time_frame>After approx. 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects with normal erectile function (IIEF-EF Â³26) After approx. 12 weeks</measure>
    <time_frame>After approx. 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects with mild Erectile Dysfunction (IIEF-EF 22-25) After approx. 12 weeks</measure>
    <time_frame>After approx. 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optional by country, the effect of vardenafil on health-related quality of life (HRQoL) using the Aging Males Symptoms (AMS) Scale</measure>
    <time_frame>After approx. 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2289</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vardenafil (Levitra, BAY38-9456)</intervention_name>
    <description>Patients with diagnosis of erectile dysfunction and metabolic syndrome who get vardenafil in routine treatment as prescribed by physician</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      n.a
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diagnosis of erectile dysfunction and metabolic syndrome who get vardenafil
        in routine treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Erectile Dysfunction (ED) patient who has newly been prescribed vardenafil (Levitra
             film-coated tablet) in accordance with the terms of the local marketing authorization.

          -  Diagnosis of erectile dysfunction at the discretion of the physician, based on the
             patients ED history.

          -  No use of any Phosphodiesterase Type 5 (PDE5) inhibitor within 1 month of study entry.

          -  Documented Metabolic Syndrome (MetS), preferably according to the definition of the
             International Diabetes Foundation.

        Exclusion Criteria:

          -  Do not follow the contraindications and warnings of the Summary of Product
             Characteristics.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Kazakhstan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Kyrgyzstan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
    <country>Israel</country>
    <country>Kazakhstan</country>
    <country>Korea, Republic of</country>
    <country>Kyrgyzstan</country>
    <country>Lebanon</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>Singapore</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Jordan</country>
    <country>Libyan Arab Jamahiriya</country>
    <country>Vietnam</country>
    <country>Yemen</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <results_reference>
    <citation>Shabsigh R, Mattern A; REVITALISE Study Group. REVITALISE: A Large Observational Study Assessing the Safety and Effectiveness of Vardenafil in Men With Erectile Dysfunction and Metabolic Syndrome. Sex Med. 2016 Sep;4(3):e135-44. doi: 10.1016/j.esxm.2016.03.027. Epub 2016 Apr 14.</citation>
    <PMID>27151768</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2010</study_first_submitted>
  <study_first_submitted_qc>April 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2010</study_first_posted>
  <last_update_submitted>October 14, 2016</last_update_submitted>
  <last_update_submitted_qc>October 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vardenafil Dihydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

